S. E. DePrimo

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

A. Norden-Zfoni, Jayesh Desai, Judith Manola et al. · Clinical Cancer Research · 2007 · 198 citations

Medicine, Oncology, Pharmacology +17

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer

S. E. DePrimo, Chad Friece, Xin Huang et al. · Journal of Clinical Oncology · 2006 · 29 citations

Medicine, Oncology, Pharmacology +17

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis

Suzanne George, Jean‐Yves Blay, Paolo G. Casali et al. · Journal of Clinical Oncology · 2008 · 16 citations

Medicine, Oncology, Pharmacology +16

Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST

A. Norden-Zfoni, Judith Manola, Jigar Desai et al. · Journal of Clinical Oncology · 2005 · 16 citations

Medicine, Oncology, Pharmacology +17

Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters

S. E. DePrimo, Ann‐Lii Cheng, Silvana Lanzalone et al. · Journal of Clinical Oncology · 2008 · 11 citations

Medicine, Oncology, Pharmacology +17